Prevention & lipids

Lipoprotein(a), high-sensitivity C-reactive protein, and risk of incident atherosclerotic cardiovascular disease (ASCVD) in individuals without standard modifiable risk factors

Eur J Prev CardiolPublished Prospective cohort study

Authors' conclusion

In SMuRF-less individuals, Lp(a) and hsCRP independently predict ASCVD risk.

Study context

Population
SMuRF-less UK Biobank participants free of CVD at baseline (no current smoking, obesity, hypertension, dyslipidemia or diabetes)1,104 (2.2%) ASCVD events
Participants
50,450 participants
Exposure
Elevated vs non-elevated Lp and high-sensitivity C-reactive protein (hsCRP)
Outcome
Incident ASCVD (nonfatal MI, nonfatal ischemic stroke or CV death)
Follow-up
15 years
Methodological detailsUK Biobank, Fine-Gray competing-risk regression
  • UK Biobank
  • Fine-Gray competing-risk regression

Main finding

As reported in the abstract

Incident ASCVD · 15 years
Subdistribution hazard ratio (95% CI)
Elevated hsCRPcohort-specific cutoffs
1.35(1.16–1.57)
Elevated Lp(a)cohort-specific cutoffs
1.24(1.06–1.45)
Concurrent elevationsjoint analysis, cohort-specific cutoffs; no evidence of interaction
1.64(1.28–2.09)

Observational data: associations, not effects.

Further findings

Incident ASCVD, clinical cutoffs (Lp(a) ≥125 nmol/L; hsCRP ≥2.0 mg/L)

ComparisonsHR (95% CI)
Concurrent elevations1.74 (1.17–2.59)
Similar patterns with clinical cutoffs

Original publication

Lipoprotein(a), high-sensitivity C-reactive protein, and risk of incident ASCVD in individuals without standard modifiable risk factors. Eur J Prev Cardiol. Published 16 April 2026. doi:10.1093/eurjpc/zwag221

Summarised from the published abstract; every number is checked against it

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.